Retatrutide is the first single-molecule triple GIP/GLP-1/glucagon receptor agonist. It carries the strongest published weight-endpoint magnitude in current research literature.
Retatrutide (LY3437943) is a single-molecule triple agonist engaging the GIP, GLP-1 and glucagon receptors. The glucagon component adds an energy-expenditure axis not present in tirzepatide or semaglutide.
Triple mechanism
- GIP receptor agonism — adipocyte insulin sensitivity.
- GLP-1 receptor agonism — satiety and glucose-dependent insulin.
- Glucagon receptor agonism — hepatic energy expenditure and lipid oxidation.
- Fatty-acid linker supports weekly research dosing published in Phase II trials.
Notable research characteristics
- Half-life ~6 days in published pharmacokinetic reports.
- Highest weight-endpoint magnitude of any published incretin to date.
- Requires cautious titration in published protocols due to added glucagon activity.
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
